Literature DB >> 23645657

The use of rituximab and bendamustine in treating chronic lymphocytic leukaemia (CLL) in end-stage renal disease (ESRD).

Jun Shoji1, Susie Q Lew.   

Abstract

A patient with a history of type 2 diabetes mellitus and chronic lymphocytic leukaemia has renal failure with large kidneys. The patient refused kidney biopsy to determine the aetiology of her renal failure. She uses peritoneal dialysis to treat renal failure. She received rituximab and bendamustine to treat chronic lymphocytic leukaemia. Adenopathy resolves with treatment and she does not experience any electrolyte disturbances or decrease in urine output as a result of chemotherapy in the setting of renal failure. Renal function did not recover with chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23645657      PMCID： PMC3669984          DOI： 10.1136/bcr-2013-009637

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  5 in total

1.  Reversible renal failure due to specific infiltration of the kidney in chronic lymphocytic leukaemia.

Authors:  M I Comerma-Coma; A Sans-Boix; E Tuset-Andújar; J Andreu-Navarro; A Pérez-Ruiz; I Naval-Marcos
Journal:  Nephrol Dial Transplant       Date:  1998-06       Impact factor: 5.992

2.  Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.

Authors:  Manuela A Bergmann; Maria E Goebeler; Michael Herold; Bertold Emmerich; Martin Wilhelm; Corinna Ruelfs; Lothar Boening; Michael J Hallek
Journal:  Haematologica       Date:  2005-10       Impact factor: 9.941

3.  Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.

Authors:  D Huhn; C von Schilling; M Wilhelm; A D Ho; M Hallek; R Kuse; W Knauf; U Riedel; A Hinke; S Srock; S Serke; C Peschel; B Emmerich
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

4.  Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.

Authors:  Brad S Kahl; Nancy L Bartlett; John P Leonard; Ling Chen; Kristen Ganjoo; Michael E Williams; Myron S Czuczman; K Sue Robinson; Robin Joyce; Richard H van der Jagt; Bruce D Cheson
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

5.  Renal failure caused by leukaemic infiltration in chronic lymphocytic leukaemia.

Authors:  J K Phillips; P S Bass; G Majumdar; D R Davies; N F Jones; T C Pearson
Journal:  J Clin Pathol       Date:  1993-12       Impact factor: 3.411
  5 in total
  2 in total

Review 1.  Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review.

Authors:  Othman Al-Sawaf; Paula Cramer; Valentin Goede; Michael Hallek; Natali Pflug
Journal:  Ther Adv Hematol       Date:  2017-03-30

2.  Pharmacokinetics of gefitinib in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis.

Authors:  Teppei Yamaguchi; Sumito Isogai; Takuya Okamura; Sakurako Uozu; Yuki Mieno; Tami Hoshino; Yasuhiro Goto; Masamichi Hayashi; Toru Nakanishi; Kazuyoshi Imaizumi
Journal:  Case Rep Oncol       Date:  2015-02-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.